ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
A phase 3 trial of PM8002, Gemcitabine, Carboplatin and Eribulin in triple-negative breast cancer, run by BioNTech SE, now recruiting.
Overview
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07173751 by BioNTech SE, with 558 participants planned, started 2025-10-30 and due to reach its primary completion in 2029-12. Interventions recorded: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin and Matching placebo.
Similar pages
not linked directly; found by shared links- TrialSafety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Shares Eribulin, BioNTech, Gemcitabine, Bristol Myers Squibb and the tag pipeline.
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
- TrialA Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
- TrialPM8002 in the Treatment of Patients With Advanced Solid Tumors
- TrialA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors